Hussein Hassan Aly

Dr. Hussein Hassan Aly

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Open access
MIMasashi Iwamoto
Masashi Iwamoto
Koichi WatashiKoichi Watashi
Koichi Watashi
STSenko Tsukuda
Senko Tsukuda
Hussein Hassan AlyHussein Hassan Aly
Hussein Hassan Aly
MFMasayoshi Fukasawa
Masayoshi Fukasawa
TWTakaji Wakita
Takaji Wakita
Hepatitis B virus (HBV) entry has been analyzed using infection-susceptible cells, including primary human hepatocytes, primary tupaia hepatocytes, and HepaRG cells. Recently, the sodium taurocholate cotransporting polypeptide (NTCP) membrane transporter was reported as an HBV entry receptor. In this study, we established a strain of HepG2 cells engineered to overexpress the human NTCP gene (HepG2-hNTCP-C4 cells). HepG2-hNTCP-C4 cells were shown to be susceptible to infection by blood-borne and cell culture-derived HBV. HBV infection was facilitated by pretreating cells with 3% dimethyl sulfoxide permitting nearly 50% of the cells to be infected with HBV. Knockdown analysis suggested that HBV infection of HepG2-hNTCP-C4 cells was mediated by NTCP. HBV infection was blocked by an anti-HBV surface protein neutralizing antibody, by compounds known to inhibit NTCP transporter activity, and by cyclosporin A and its derivatives. The infection assay suggested that cyclosporin B was a more potent inhibitor of HBV entry than was cyclosporin A. Further chemical screening identified oxysterols, oxidized derivatives of cholesterol, as inhibitors of HBV infection. Thus, the HepG2-hNTCP-C4 cell line established in this study is a useful tool for the identification of inhibitors of HBV infection as well as for the analysis of the molecular mechanisms of HBV infection.

1 March 2009 in Journal of Hepatology
Verified
Journal Article
Closed access
YMYoshiki Murakami
Yoshiki Murakami
Hussein Hassan AlyHussein Hassan Aly
Hussein Hassan Aly
Atsushi TajimaAtsushi Tajima
Atsushi Tajima
IIIturo Inoue
Ituro Inoue
KSKunitada Shimotohno
Kunitada Shimotohno

1 January 2007 in Journal of Hepatology
Verified
Journal Article
Closed access
Hussein Hassan AlyHussein Hassan Aly
Hussein Hassan Aly
KWKoichi Watashi
Koichi Watashi
MHMakoto Hijikata
Makoto Hijikata
HKHiroyasu Kaneko
Hiroyasu Kaneko
YTYasutugu Takada
Yasutugu Takada
KSKunitada Shimotohno
Kunitada Shimotohno

15 May 2021 in Microbiology and Immunology
Verified
Journal Article
Closed access
PDF file
AEAshraf Elbahrawy
Ashraf Elbahrawy
MIMarwa K. Ibrahim
Marwa K. Ibrahim
AEAhmed Eliwa
Ahmed Eliwa
MAMohamed Alboraie
Mohamed Alboraie
AMAli Madian
Ali Madian
Hussein Hassan AlyHussein Hassan Aly
Hussein Hassan Aly

1 November 2007 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
KWKoichi Watashi
Koichi Watashi
DIDaisuke Inoue
Daisuke Inoue
MHMakoto Hijikata
Makoto Hijikata
KGKaku Goto
Kaku Goto
Hussein Hassan AlyHussein Hassan Aly
Hussein Hassan Aly
KSKunitada Shimotohno
Kunitada Shimotohno
Hepatitis C virus (HCV) is a major causative agent of hepatocellular carcinoma. HCV genome replication occurs in the replication complex (RC) around the endoplasmic reticulum membrane. However, the mechanisms regulating the HCV RC remain widely unknown. Here, we used a chemical biology approach to show that estrogen receptor (ESR) is functionally associated with HCV replication. We found that tamoxifen suppressed HCV genome replication. Part of ESRα resided on the endoplasmic reticulum membranes and interacted with HCV RNA polymerase NS5B. RNA interference-mediated knockdown of endogenous ESRα reduced HCV replication. Mechanistic analysis suggested that ESRα promoted NS5B association with the RC and that tamoxifen abrogated NS5B-RC association. Thus, ESRα regulated the presence of NS5B in the RC and stimulated HCV replication. Moreover, the ability of ESRα to regulate NS5B was suggested to serve as a potential novel target for anti-HCV therapeutics.

8 September 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
CLChean Ring Leong
Chean Ring Leong
KFKenji Funami
Kenji Funami
HOHiroyuki Oshiumi
Hiroyuki Oshiumi
DMDeng Mengao
Deng Mengao
HTHiromi Takaki
Hiromi Takaki
Tsukasa SeyaTsukasa Seya
Tsukasa Seya
Interferon-stimulated gene of 20 kDa protein (ISG20) degrades RNA of hepatitis B virus to impede the replication of HBV in vitro and in vivo Interferon-stimulated gene of 20 kDa protein (ISG20) degrades RNA of Hepatitis B virus to impede the replication of HBV in vitro and in vivo